GMP Compliance for Production of CB.Hep-1 Monoclonal Antibody as a Biological Reagent - - BioPharm International


GMP Compliance for Production of CB.Hep-1 Monoclonal Antibody as a Biological Reagent

Figure 6. Comparison of Regulations for Monoclonal Antibodies
In Figure 6, we see that regulations covering the use of monoclonal antibodies are the same in both cases; its demanding features are the same. We also took into account the regulations as have been previously noted.

However, when analyzing the higher cost of each assay made in the process of a monoclonal antibody and following all the rest of the required analyses, we arrive at the conclusion that it is quite high. We could ask: "Why it is necessary to maintain the same regulations for MAb use as a reagent to purify biologicals?" The recommendations for characterization and testing of MAbs used as parenterals are, of necessity, very stringent. Not all of them would be applicable to MAbs that are used as reagents in drug manufacturing.

To provide an adequate description of the manufacturing technology used in the production of the MAb, to ensure satisfactory performance of the reagent during the process, and to assess its potential impact on the biological safety, quality, and purity, the production of MAbs includes the following phases:
1. Development and characteri-zation of the cell line
2 Establishment of the cell banks
3. Production in animals (ascites fluid)
4. MAb purification
5. MAb linked to Sepharose CL-4B

The basic elements of compliance include: written SOPs, flowcharts, the immunoaffinity matrix, and Quality Control (QC) and Process Control (PC) specifications. The written SOPs describe each operation. See Figure 4 where some of the SOPs used in our process, including, approval authority, change control, history files, and standard formats, are listed.13 The flowchart for the production of anti-HBsAg monoclonal antibody and the immunoaffinity matrix is shown in Figure 1. Here, the QC and the PC stand for controls that are carried out in every step.

Although experts expound that in the future all the MAbs can be delivered and certificated according to existing regulations, we consider that the regulations for the monoclonal antibodies used as reagents could resemble the following:

Cell Line Characterization and Development

This information is important because it will determine, in part, what adventitious agents tests should be performed in those cases where extensive testing may be necessary. (The suppliers certify the fetal bovine serum as free of bovine viruses, Bovine Spongiform Encephalopathy (BSE), and mycoplasmas.)

  • Other characterization, such as subclass and molecular weight determination, should be performed early so that appropriate identity tests can be developed for production lots.
  • Major concerns in cell bank establishment in-clude verification of the identity and clonality of the banked cells and acceptable degrees of freedom from adven-titious agents.

In our case, CB.Hep-1 MCB is free from adventitious agents and the MAb characterization corresponds to the MAb secreted by the original cell line; therefore, it can be used in the rHBsAg purification process. Aleman, et al. 2000, publishes these results.11

Production in Animals (Ascites fluid)

In general, steps should be taken to prevent or control contamination (e.g., virus, bacteria, fungi, myco-plasma) introduced during the production process. Recommended characterization of the MAb production process, again, will depend on the subsequent downstream processing of the drug substance.

Isolation and Purification

For reagents, the predominant concern is whether the MAb purity is sufficient to prevent the carryover of in-process contaminants to the drug substance or product. Consistent production of a reasonably pure reagent should be demonstrated to assure adequate and uninterrupted performance in the production of the drug substance. Downward trends of the MAb lots in purity, integrity, and binding properties have been investigated. Chemical impurities originated from buffers, columns, and media, as well as host cell protein, should be monitored and minimized to avoid contamination of the bulk drug substance.

blog comments powered by Disqus



Bristol-Myers Squibb and Five Prime Therapeutics Collaborate on Development of Immunomodulator
November 26, 2014
Merck Enters into Licensing Agreement with NewLink for Investigational Ebola Vaccine
November 25, 2014
FDA Extends Review of Novartis' Investigational Compound for Multiple Myeloma
November 25, 2014
AstraZeneca Expands Biologics Manufacturing in Maryland
November 25, 2014
GSK Leads Big Pharma in Making Its Medicines Accessible
November 24, 2014
Author Guidelines
Source: BioPharm International,
Click here